🔎 Trials Near Me

Akèy › Obèsite › Florid › Ocala

Etid klinik pou Obèsite nan Ocala, FL

7 etid pou Obèsite ap chèche patisipan nan sit nan ak bò kote Ocala (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

Ap rekriteFaz 3
  • Ocala Cardiovascular Research, Ocala
Laj 18 a 99 · Tout sèks · Mizajou Sep 16, 2026 · NCT07037459

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Ap rekriteFaz 2
  • Renstar Medical Research, Ocala
Laj 18 a 75 · Tout sèks · Mizajou Sep 14, 2026 · NCT06897475

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Ap rekriteFaz 3Volontè an sante akeyi
  • ACCOMPLISH-2 Research Site, Ocala
Laj 18 a 79 · Tout sèks · Mizajou Sep 11, 2026 · NCT07654374

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Ap rekriteFaz 3
  • Renstar Medical Research, Ocala
Laj 18 a 99 · Tout sèks · Mizajou Sep 3, 2026 · NCT07684235

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

Ap rekriteFaz 3
  • Ocala Cardiovascular Research, Ocala
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT07567001

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

Ap rekriteFaz 3
  • ACCOMPLISH-1 Research Site, Ocala
Laj 18 a 79 · Tout sèks · Mizajou Aug 10, 2026 · NCT07654361

Etid Obèsite nan lòt vil

Lòt etid nan Ocala

Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.